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Abstract
Introduction: Anticonvulsant drugs taken by pregnant women to prevent seizures are among the
most common causes of potential harm to the fetus. While the immediate harmful effects manifesting
as congenital abnormalities are well known, the long-term effects on growth of children exposed
in utero to antiepileptic drugs are still uncertain.
Case presentation: A 7-year-old boy presented to our clinic with severe short stature. His height
was 110.4 cm (−2.4 standard deviation score), with a target height of 177 cm (+0.35 standard
deviation score). Height corrected for target height was −2.75 standard deviation score. He
presented with mild dysmorphic facial features, hypospadias and postnatal onset of severe growth
retardation. Biochemical and endocrine tests were in the normal range. The child was exposed
in utero to both carbamazepine and phenobarbital.
Conclusion: This case report shows for the first time that prenatal exposure to antiepileptic drugs
may induce postnatal onset of severe growth retardation, suggesting the need for growth and
endocrine monitoring of offspring exposed in utero to anticonvulsant drugs.
Introduction
Epilepsy is common, affecting 0.5% to 1% of the
population. Of these, a third are women in reproductive
age, and approximately 1 in 250 pregnancies are exposed
to antiepileptic drugs. In utero exposure to antiepileptic
drugs can result in several different teratogenic effects
including major malformations, dysmorphic facial fea-
tures, intrauterine growth retardation, learning and
behavioral problems. We report on a child exposed
in utero to both carbamazepine and phenobarbital. He
presented with mild dysmorphic facial features, hypospa-
dias and postnatal onset of growth retardation.
Case presentation
A 7-year-old boy presented to our clinic with short stature.
His height was 110.4 cm (−2.4 standard deviation score
(SDS)), with a target height of 177 cm (+0.35 SDS). Height
corrected for target height was −2.75 SDS. His weight was
16.5 kg. Body mass index (BMI) was 13.5 (−1.8 SDS). He
wasbornattermafteranuneventfulpregnancy.Birthweight
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(page number not for citation purposes)was 4260 g (+1.3 SDS), birth length was 53 cm (+1.1 SDS)
andbirthheadcircumferencewas37cm(+1.3SDS).Hewas
born with hypospadias and underwent surgery at the age of
two years. During pregnancy, his mother had undergone
antiepileptictherapywithcarbamazepine(200mgbid)and
phenobarbital(100mgbid).Hisgrowthwasnormalduring
the first 12 months of age, thereafter it slowed down
progressively (Figure 1). On physical examination, ocular
hypertelorism, arched eyebrows, epicanthal folds, broad
nasal bridge, low-set ears, and shortness of the thumb were
noted (Figure 2). Bone age was six years. Neurocognitive
function was normal. Liver and renal function test results,
electrolytes, calcium, phosphorus, and celiac disease mar-
kers were within the normal range. Urine examination was
normal and thyroid function tests were normal. Arginine
and growth hormone releasing hormone (GHRH) +
arginine testing showed normal growth hormone (GH)
responses (GH peaks 25 mg/L and 25.3 mg/L, respectively;
normal values ≥10 mg/L and 20 mg/L, respectively). Insulin-
like growth factor-I (IGF-I) concentrations were in the low
normal range (90 mg/L, −1.8 SDS), whereas IGFBP-3 levels
were within the normal range (2.9 mg/L, +0.2 SDS). Renal
and cardiac ultrasound scans were normal. Skeletal X-rays
showed a short first metacarpal bone but no sign of skeletal
dysplasias. Dysmorphologic evaluation did not reveal any
particular syndrome. Chromosome analysis disclosed a
normal 46,XY, karyotype.
Discussion
Data on the effects of prenatal exposure to carbamazepine
and/or phenobarbital are conflicting. In a retrospective
study of 375 children aged from six months to 16 years
born to 219 mothers with epilepsy, Kini et al. [1] reported
short stature in 6.5% of children exposed to
Figure 1. Postnatal growth of the child exposed in utero to
carbamazepine and phenobarbital.
Figure 2. Patient’s phenotype.
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therapy. In a prospective observational study across 25
epilepsy centers in the USA and UK, Meador et al. [2]
observed that more adverse outcomes were observed in
pregnancies with in utero valproate exposure. In children
exposed in utero to carbamazepine, the following con-
genital malformations have been reported: absent kidney,
duplicate renal pelvis, hypospadias, and inguinal hernia.
In a cohort of female patients with epilepsy, Artama et al.
[3] reported that the risk for congenital malformations was
not elevated in offspring of mothers using carbamazepine,
oxcarbazepine, or phenytoin (as monotherapy or poly-
therapy without valproate). In rats, Manent et al. [4]
reported that prenatal exposure to vigabatrin and valpro-
ate, which act on GABA signaling, induces hippocampal
and cortical dysplasias, which are likely to result from a
neuronal migration defect and neuronal death. In contrast,
offspring of rats exposed to carbamazepine showed no
clear-cut evidence of dysplasias. Wide et al. [5] found a
significant reduction in weight, head circumference and
length, which tended to improve toward the first year and
was marked in babies exposed to polytherapy and also in
babies exposed to carbamazepine monotherapy. However,
it has to be pointed out that nearly all studies on the
adverse fetal effects of antiepileptic drugs have methodo-
logical shortcomings, including retrospective or inade-
quately prospective design, insufficient sample size,
recruitment and assessment bias, limited length of
follow-up, questionable choice of controls, and failure to
account for potential confounders [6].
Our case is consistent with two previous reports showing
either impaired physical growth in infants exposed to
anticonvulsant drugs in utero in spite of normal birth size
[7] or increased frequency of major malformations,
microcephaly, and growth retardation in infants exposed
to carbamazepine compared with control infants [8].
However, the severity of growth retardation and the full
investigation of GH-IGF-I axis make our case unique. The
finding of reduced IGF-I levels despite normal GH peak
responses to stimulation tests raises the issue of a potential
disrupting effect of the in utero antiepileptic exposure on
postnatal GH-IGF-I axis function.
Conclusion
This case report shows for the first time that prenatal
exposure to antiepileptic drugs may induce postnatal
onset of severe growth retardation, thus suggesting the
need for growth and endocrine monitoring of offspring
exposed in utero to anticonvulsant drugs.
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